Vitrakvi deemed ‘not cost-effective’ by NICE
admin 17th January 2020 Uncategorised 0The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
More: Vitrakvi deemed ‘not cost-effective’ by NICE
Source: News
